Fig. 1.

Overall survival of the forty-three patients with CHP was assessed in relation to (A) annual decline in FVC, (B) annual decline in DLco and (C) BAL lymphocyte count. Differences between the two groups were evaluated using a log-rank test. Number at risk is the number of patients whose follow-up continues at each time point. ROC analysis for (D) annual decline in FVC (area under the curve (AUC) = 0.796, p = 0.001), (E) annual decline in DLco (AUC = 0.782, p = 0.005) and (F) BAL lymphocyte count (AUC = 0.752, p = 0.006) to discriminate the patients who die within five year from the patients who survive